NEXALIN TECHNOLOGY INC
NXLNASDAQTrading Snapshot
- Day Range
- $1.62 – $1.73
- 52-Week Range
- $1.59 – $49.50
- Volume (shares)
- 44,452
- Avg Volume (shares)
- —
- Shares Outstanding
- 830,000
- Next Earnings
- 2026-11-13
Fundamentals Snapshot
- Annual Revenue
- $301,647
- Last Q Revenue
- $12,161
- P/E Ratio
- —
- P/S Ratio
- 7.9x
- EPS (TTM)
- $-0.47
- Dividend Yield
- —
- Dilution (1yr)
- +102.1%
NEXALIN TECHNOLOGY INC
NXL
StockOtter · stockotter.spaceAbout NEXALIN TECHNOLOGY INC
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease
Results from the randomized, double-blind, sham-controlled TRANSFORM-AD study published in the Journal of Alzheimer's Disease, a recognized international peer-reviewed journal Statistically significant improvement in sle
Nuix Launches Agentic AI in Nuix Neo with Audit Trail Built In
SYDNEY, Oct. 21, 2026 /PRNewswire/ -- Nuix (ASX: NXL), a provider of investigative analytics and intelligence software, today launched the Nuix Neo AI Agent. Nuix software analyses large volumes of unstructured data, suc
Nexalin Technology (NASDAQ:NXL) vs. IceCure Medical (NASDAQ:ICCM) Financial Analysis
Nexalin Technology (NASDAQ: NXL - Get Free Report) and IceCure Medical (NASDAQ: ICCM - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses bas
Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing
Company remains focused on its transition toward commercial revenue generation and the advancement of its U.S. clinical programs Company remains focused on its transition toward commercial revenue generation and the adva
Critical Survey: Enovis (NYSE:ENOV) vs. Nexalin Technology (NASDAQ:NXL)
Nexalin Technology (NASDAQ: NXL - Get Free Report) and Enovis (NYSE: ENOV - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the
Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation
Agreement establishes an initial 100-device commercialization program for the ANVISA-approved Nexalin Sync™ across seven countries and more than 300 million people, with a structured pricing framework and a mechanism for